The European bladder cancer market is estimated to grow modestly, at a CAGR of around 9.3%, during the forecast period. The growth of the market is attributed to well-developed healthcare infrastructure coupled with significant healthcare expenditure and growing prevalence and incidence of bladder cancer across many European economies.